Cover Image

Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers

Aims: The EMPA-REG OUTCOME trial demonstrated that the sodium-glucose cotransporter-2 inhibitor (SGLT2) empagliflozin reduces the risk of cardiovascular (CV) and kidney outcomes in patients with type 2 diabetes. We previously developed the parameter response efficacy (PRE) score, which translates dr...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sok Cin Tye (Author), Sieta T. de Vries (Author), Christoph Wanner (Author), Petra Denig (Author), Hiddo J. L. Heerspink (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers
by: Sok Cin Tye, et al.
Published: (2022)

Less Timely Initiation of Glucose-Lowering Medication Among Younger and Male Patients With Diabetes and Similar Initiation of Blood Pressure-Lowering Medication Across Age and Sex: Trends Between 2015 and 2020
by: Martina Ambrož, et al.
Published: (2022)

Older Age, Polypharmacy, and Low Systolic Blood Pressure Are Associated With More Hypotension-Related Adverse Events in Patients With Type 2 Diabetes Treated With Antihypertensives
by: Martina Ambrož, et al.
Published: (2021)

Progress and opportunities in measuring the burden of Chronic Kidney Disease
by: Priya Vart, et al.
Published: (2022)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
by: Daniel H. Van Raalte, et al.
Published: (2022)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
by: Hilmi Alnsasra, et al.
Published: (2023)

Quantifying the integrated physiological effects of endothelin-1 on cardiovascular and renal function in healthy subjects: a mathematical modeling analysis
by: Hongtao Yu, et al.
Published: (2024)

Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy
by: Colbert GB, et al.
Published: (2023)

The Neutrophil to Lymphocyte Ratio: An Ideal Marker for Early Diagnosis and Short-Term Prognosis of Acute Kidney Injury?
by: Susanne M. Lang, et al.
Published: (2021)

Reply to "The Neutrophil-to-Lymphocyte Ratio: An Ideal Marker for Early Diagnosis and Short-Term Prognosis of Acute Kidney Injury?"
by: Jiefu Zhu, et al.
Published: (2021)

Prognostic Cardiovascular Markers in Chronic Kidney Disease
by: Szu-Chia Chen, et al.
Published: (2018)

Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
by: Sanon VP, et al.
Published: (2017)

The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
by: Chang Chu, et al.
Published: (2019)

Kinetics of endothelin-1 and effect selective ETA antagonism on ETB activation: a mathematical modeling analysis
by: K. Melissa Hallow, et al.
Published: (2024)

Empagliflozin increases kidney weight due to increased cell size in the proximal tubule S3 segment and the collecting duct
by: Frederick Sinha, et al.
Published: (2023)

Cost-effectiveness of Empagliflozin Compared to Liraglutide in Iran Based on Cardiovascular Outcome Trials in Type 2 Diabetes Mellitus
by: Nayyereh Ayati, et al.
Published: (2022)

Comparing Normal and Multiple Sclerotic Patients Short Term Memory
by: Mahboubeh Parsaeian, et al.
Published: (2006)

The Short Term Cardiovascular and Pulmonary Responses to Exercise in Young Adults
by: Ambreen Khalid, et al.
Published: (2019)

Early Markers of Cardiovascular Risk in Autosomal Dominant Polycystic Kidney Disease
by: Silvia Lai, et al.
Published: (2017)

Effects of SGLT2 inhibition via empagliflozin on cognitive and physical impairment in frail diabetic elders with chronic kidney disease
by: Pasquale Mone, et al.
Published: (2024)

Role of Haematological Markers in Predicting Short-term Outcome in Neonates with Birth Asphyxia
by: Sharath Keerthy, et al.
Published: (2019)

Empagliflozin in the treatment of type 2 diabetes: evidence to date
by: Shubrook JH, et al.
Published: (2015)

Stability-indicating HPLC-DAD method for the determination of empagliflozin
by: Shilpi Pathak, et al.
Published: (2021)

PIMS - symptoms and short/long-term gastrointestinal and cardiovascular system complications
by: Aleksandra Grudzińska, et al.
Published: (2023)

Influence of Short-Term Fasting on the Changes in Women's Cardiovascular Functional Parameters
by: Sandra Bardauskienė, et al.
Published: (2018)

Changes in salivary markers during basketball long-term and short-term training periods: a systematic review
by: Paulius Kamarauskas, et al.
Published: (2021)

Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting
by: Yueh-Ting Lee, et al.
Published: (2021)

Comparative Safety Analysis of Empagliflozin in Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease versus Normal Kidney Function: A Nationwide Cohort Study in Korea
by: Ha Young Jang, et al.
Published: (2023)

Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use
by: António Cabral Lopes, et al.
Published: (2024)

Acute Kidney Injury and Long-Term Risk for Cardiovascular Events in Patients after Kidney Transplantation
by: Ruth Rahamimov, et al.
Published: (2019)

Progress of patients hospitalized with acute heart failure treated with empagliflozin
by: Manuel Raya-Cruz, et al.
Published: (2024)

Empagliflozin Protects against Haloperidol Experimentally-Induced Ovarian Toxicity
by: Walaa Yehia Abdelzaher, et al.
Published: (2023)

The role of empagliflozin in the management of type 2 diabetes by patient profile
by: Hedrington MS, et al.
Published: (2015)

Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
by: Munir KM, et al.
Published: (2016)

Empagliflozin-A New Chance for Patients with Chronic Heart Failure
by: Klaudia Kowalska, et al.
Published: (2021)

Susceptibility to short-term ozone exposure and cardiovascular and respiratory mortality by previous hospitalizations
by: Auriba Raza, et al.
Published: (2018)

The outcome of short-term low-dose aspirin treatment in Kawasaki disease based on inflammatory markers
by: Jae Won Yoo, et al.
Published: (2017)

Acute Kidney Injury: Clinical Characteristics and Short-Term Outcomes in 1,519 Patients
by: Christina Montgomerie, et al.
Published: (2022)

Short-term blood pressure variability as a potential therapeutic target for kidney disease
by: Ye Eun Ko, et al.
Published: (2023)

International Variability of Renal and Cardiovascular Outcomes and Mortality in Patients with Type 2 Diabetes Mellitus in Europe
by: Stefanie Thöni, et al.
Published: (2023)